Patent ID: 8343953
Filing Date: 2013-01-01
Classification: A61P,C07D

Abstract:
1. A method for (a) the treatment of a disease or condition in which the modulation of ROCK kinase or protein kinase p70S6K is indicated; and/or (b) the treatment of a subject or patient population having or at risk of suffering from a disease or condition in which the modulation of ROCK kinase or protein kinase p70S6K is indicated; which method comprises administering to a subject in need thereof an effective amount of a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof; wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R and wherein the disease or condition is selected from: tumour metastasis; tumour invasion; tumour progression; tumour adhesion; actinomycin contractility-dependent tumour metastasis, invasion or progression; cell transformation; ROCK-mediated tumour metastasis, invasion, progression or adhesion; ROCK-mediated actinomycin contractility-dependent tumour metastasis, invasion or progression; ROCK-mediated cell transformation; cancer; a cardiovascular disease or condition; a disease or condition which comprises muscle dysfunction; a disease or condition which comprises inflammation; a CNS disease or condition; an infectious disease or condition; insulin resistance; graft protection; diabetes; asthma; pulmonary vasoconstriction; glaucoma; fibroses; immune dysfunction; tissue damage; chromosome 17q23 amplification; Peutz-Jeghers syndrome; LKB1 mutation(s); BRCA1 mutation(s); BRCA2 mutation(s); dysfunctional apoptotic programmes; growth factor receptor signal transduction, overexpression and activation in tumour tissue; a metabolic disease or disorder; those associated with abnormal cell proliferation and/or metabolism; and neuronal disorders.